Skip to main content
Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method AMERICAN JOURNAL OF HEMATOLOGY Sidana, S., Jevremovic, D., Ketterling, R. P., Tandon, N., Dispenzieri, A., Gertz, M. A., Greipp, P. T., Baughn, L. B., Buadi, F. K., Lacy, M. Q., Morice, W., Hanson, C., Timm, M., Dingli, D., Haynnan, S. R., Gonsalves, W., Kapoor, P., Kyle, R. A., Leung, N., Go, R. S., Lust, J. A., Rajkumar, S., Kumar, S. K. 2019; 94 (4): 424–30

Abstract

Trisomies of odd numbered chromosomes are seen in nearly half of patients with multiple myeloma (MM) and typically correlate with a hyperdiploid state and better overall survival (OS). We compared DNA ploidy of monoclonal plasma cells (as a surrogate for the presence of trisomies) assessed simultaneously by PCPRO (plasma cell proliferative index), a novel method that estimates DNA index by multi-parametric flow cytometry to fluorescence in situ hybridization (FISH) in 1703 patients with plasma cell disorders. The distribution of ploidy was hyperdiploid: 759 (45%), diploid 765 (45%), hypodiploid: 71 (4%), tetraploid/near-tetraploid: 108 (6%). FISH identified trisomies in 82% (621/756) of patients with hyperdiploidy by PCPRO and no trisomy by FISH was observed in 88% (730/834) of patients without hyperdiploidy. 95% (795/834) of patients without hyperdiploidy on PCPRO had one or less trisomy by FISH. Sensitivity and specificity of PCPRO for detecting hyperdiploidy was 86% (621/725) and 84% (730/865), respectively. Sensitivity increased to 94% (579/618) for patients with more than one trisomy. Newly diagnosed MM patients with hyperdiploidy on PCPRO (147/275) had better OS compared to nonhyperdiploid patients (median not reached vs 59?months, P = 0.008) and better progression free survival (median: 33 vs 23?months, P = 0.03). Within the hyperdiploidy group, patients with high-hyperdiploidy (DNA index: 1.19-1.50) versus those with low-hyperdiploidy (DNA index: 1.05-1.18) had superior OS (3 year OS of 88% vs 68% P = 0.03). Ploidy assessment by flow cytometry can provide rapid, valuable prognostic information and also reduces the number of copy number FISH probes required and hence the cost of FISH.

View details for DOI 10.1002/ajh.25391

View details for Web of Science ID 000460663200018

View details for PubMedID 30592078